Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs?
Summary
The Food and Drug Administration (FDA) has warned Empower Pharmacy for making large amounts of copies of popular weight-loss drugs without following federal rules. This is the first time the FDA has stepped into the debate about when a pharmacy’s custom drug-making becomes illegal mass production of patented medicines.Key Facts
- Empower Pharmacy makes copies of weight-loss drugs that are FDA-approved by companies like Eli Lilly and Novo Nordisk.
- Compounding pharmacies usually customize drugs for individual patients, but they are not reviewed by the FDA like regular drugs.
- The FDA allowed compounding pharmacies to make copies during a drug shortage in 2022 when big companies couldn’t keep up.
- The FDA declared the drug shortage over in 2025, leading many pharmacies to stop making these copies.
- Smaller pharmacies continued making versions by tweaking the drugs slightly, claiming it helps individual patients.
- Eli Lilly has sued Empower Pharmacy, calling their copies fake personalized drugs and mass-produced knockoffs.
- The FDA’s warning letter claims Empower did not get proper doctor instructions and made large quantities, violating federal law.
- This FDA action marks the first direct federal enforcement against what it sees as mass-copying of patented drugs by compounding pharmacies.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
